SO
Solara Active Pharma Sciences Ltd (SOLARA)
₹628.25
Mkt cap
₹3,050 Cr
P/E ratio
64.40
P/B
2.12
Div yield
0.00%
ROE
−0.13%
ROCE
4.86%
EPS (TTM)
₹9.76
Book value
₹296
52W range
422–774
Sector
Healthcare
Price history
Previous close
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs. [1] It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company. [2]
NSE SOLARABSE 541540
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−18.83% from high₹628
₹422+48.87% from low₹774
Current
₹628.25
Prev close
₹640.60
Day
−1.93%
Price performance
1D
−1.45%
1W
−8.46%
1M
+1.98%
3M
−1.36%
6M
+11.88%
1Y
+10.18%
YTD
+7.94%
Financials
Revenue, profit & margin
P/E ratio
64.4×
SOLARA is 98% above the sector median of 32.5×
SOLARA64.4×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 | 417 | |
| YoY Sales growth | +26% | -46% | -21% | +3% | -18% | +42% | -9% | -12% | -10% | +16% | +42% | +20% | +33% | |
| Expenses | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 | 340 | |
| Operating Profit | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 | 77 | |
| OPM % | 9% | -76% | 3.3% | 12% | 18% | 19% | 17% | 18% | 11% | 11% | 15% | 16% | 18% | |
| Other Income | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 | -4 | |
| Interest | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 | 18 | |
| Depreciation | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 | 27 | |
| Profit before tax | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | 28 | |
| Tax % | 0% | 0% | 53% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | 28 | |
| EPS in Rs | -4.39 | -70.42 | -65.30 | -3.74 | 2.22 | 2.24 | -0.58 | 2.91 | -2.79 | -4.82 | 2.65 | 3.38 | 5.86 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −7.33% · closed higher next day 0 of last 1
| Q2FY27 | |
|---|---|
| Broadcast | 16 Oct '26◦ |
| Earnings day | −7.33% |
| +1 day | −6.95% |
| +5 days | −8.61% |
| +15 days | −4.05% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202641.93%Promoter
Promoters41.93%
FIIs10.71%0.81
DIIs3.89%0.15
Public43.46%0.67
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.76 | 4,52,251 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.16 | 1,78,374 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.53 | 1,23,980 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.42 | 1,19,700 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.47 | 1,16,119 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.81 | 1,14,316 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Solara Active | ₹628.25 | 64.43 | 3,050 | 0.00% | 28 | +426.34% | 417 | +33.11% | 4.86% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,983 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports9
Concall transcripts57
TranscriptOct 2026PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025RECMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 18 Nov - Solara Active Pharma Sciences Limited has informed about copy of Newspaper Advertisement published with respect to dispatch of the Notice of Postal Ballot dated November …Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 17 NovAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 23 Oct - Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Oct - Solara Active Pharma Sciences Limited has informed regarding the copy of Newspaper publication informing about Final Reminder-cum-Forfeiture Notice for the payment of First ....Final Reminder-Cum-Forfeiture Notice To The Holders Of Partly Paid-Up Equity Shares Of The Company. 17 Oct - Final reminder for partly paid rights shares: pay ₹131.25 and ₹112.50 by Nov 5, 2026.






